Neuraminidase inhibitors for influenza complications

Chris Del Mar, Peter Doshi, Rokuro Hama, Mark Jones, Tom Jefferson, Carl Heneghan, Igho Onakpoya, Jeremy Howick

Research output: Contribution to journalLetterResearchpeer-review

Abstract

In their Comment (Aug 2, p 386),1 Jonathan Nguyen-Van-Tam and colleagues suggest that findings from our Cochrane review2 and a study of observational data3 are consistent. In our review, which was based on full clinical study reports of all manufacturer-sponsored randomised trials, we did not find evidence that neuraminidase inhibitors improve important outcomes of influenza, whereas the Roche-funded individual analysis of a subset of retrospective case reports suggested that neuraminidase inhibitors do have some beneficial effect.
Original languageEnglish
Pages (from-to)1260-1261
Number of pages2
JournalThe Lancet
Volume384
Issue number9950
DOIs
Publication statusPublished - 4 Oct 2014

    Fingerprint

Cite this

Del Mar, C., Doshi, P., Hama, R., Jones, M., Jefferson, T., Heneghan, C., ... Howick, J. (2014). Neuraminidase inhibitors for influenza complications. The Lancet, 384(9950), 1260-1261. https://doi.org/10.1016/S0140-6736(14)61761-X